Catalog peptides market was valued at US$ 235.59 million in 2020 and is projected to grow US$ 403.75 million at a CAGR of 8% by 2027. The catalogue peptide market is witnessing growth due to technological advances that aid in the cost-effective manufacture of peptides. Previously, peptides were synthesized from natural sources such as porcine-derived adrenocorticotropic hormone (ACTH) or bovine pituitary, and bovine or canine pancreatic insulin. Growing research activities to address unmet medical needs in various therapeutic areas, raising the burden of chronic diseases and increasing investment and funding for protein-based research are among the key factors driving the market growth. Nevertheless, the absence of a coherent collection of regulations restrains business development. This study analyses the global catalog peptides market dynamics in a detailed manner to identify current trends and drivers, growth opportunities and potential challenges to the key stakeholders in the operating market. In addition, PBI has analyzed the global market to better equip customers with possible investment opportunities across region and consumer unmet needs. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in Catalog peptides products.
In February 2017 to expand its product portfolio by incorporating proteins, antibodies and enzyme-linked immunosorbent assays (ELISA) into GenWay’s product portfolio and to become a key provider of proteomic solutions on the market.
In January 2017, the PolyPeptide Group announced the completion of its acquisition of the peptides business and operations of Lonza in Braine-l’Alleud, Belgium.